دورية أكاديمية
Differential changes in end organ immune cells and inflammation in salt-sensitive hypertension: effects of lowering blood pressure.
| العنوان: | Differential changes in end organ immune cells and inflammation in salt-sensitive hypertension: effects of lowering blood pressure. |
|---|---|
| المؤلفون: | Navaneethabalakrishnan S; Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX, U.S.A., Goodlett BL; Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX, U.S.A., Smith HL; Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX, U.S.A., Cardenas A; Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX, U.S.A., Burns A; Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX, U.S.A., Mitchell BM; Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX, U.S.A. |
| المصدر: | Clinical science (London, England : 1979) [Clin Sci (Lond)] 2024 Jul 17; Vol. 138 (14), pp. 901-920. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Portland Press on behalf of the Medical Research Society and the Biochemical Society Country of Publication: England NLM ID: 7905731 Publication Model: Print Cited Medium: Internet ISSN: 1470-8736 (Electronic) Linking ISSN: 01435221 NLM ISO Abbreviation: Clin Sci (Lond) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Portland Press on behalf of the Medical Research Society and the Biochemical Society Original Publication: London, Medical Research Society. |
| مواضيع طبية MeSH: | Hypertension*/immunology , Hypertension*/physiopathology , Hypertension*/drug therapy , Hypertension*/chemically induced , Mice, Inbred C57BL* , Blood Pressure*/drug effects , Sodium Chloride, Dietary*/adverse effects , Kidney*/immunology , Kidney*/drug effects , Inflammation*/immunology, Animals ; Male ; Female ; Lymphangiogenesis/drug effects ; Antihypertensive Agents/pharmacology ; Mice ; Hydralazine/pharmacology ; NG-Nitroarginine Methyl Ester/pharmacology ; Disease Models, Animal ; Gonads/drug effects |
| مستخلص: | We reported that salt-sensitive hypertension (SSHTN) is associated with increased pro-inflammatory immune cells, inflammation, and inflammation-associated lymphangiogenesis in the kidneys and gonads of male and female mice. However, it is unknown whether these adverse end organ effects result from increased blood pressure (BP), elevated levels of salt, or both. We hypothesized that pharmaceutically lowering BP would not fully alleviate the renal and gonadal immune cell accumulation, inflammation, and lymphangiogenesis associated with SSHTN. SSHTN was induced in male and female C57BL6/J mice by administering nitro-L-arginine methyl ester hydrochloride (L-NAME; 0.5 mg/ml) in their drinking water for 2 weeks, followed by a 2-week washout period. Subsequently, the mice received a 3-week 4% high salt diet (SSHTN). The treatment group underwent the same SSHTN induction protocol but received hydralazine (HYD; 250 mg/L) in their drinking water during the diet phase (SSHTN+HYD). Control mice received tap water and a standard diet for 7 weeks. In addition to decreasing systolic BP, HYD treatment generally decreased pro-inflammatory immune cells and inflammation in the kidneys and gonads of SSHTN mice. Furthermore, the decrease in BP partially alleviated elevated renal and gonadal lymphatics and improved renal and gonadal function in mice with SSHTN. These data demonstrate that high systemic pressure and salt differentially act on end organ immune cells, contributing to the broader understanding of how BP and salt intake collectively shape immune responses and highlight implications for targeted therapeutic interventions. (© 2024 The Author(s).) |
| References: | Cell Res. 2015 Aug;25(8):893-910. (PMID: 26206316) Hypertension. 2016 Sep;68(3):e7-e46. (PMID: 27443572) Lancet. 2019 May 11;393(10184):1958-1972. (PMID: 30954305) Cell Rep. 2017 Oct 24;21(4):1009-1020. (PMID: 29069584) Circ Res. 2016 Apr 15;118(8):1233-43. (PMID: 26988069) Curr Med Sci. 2023 Aug;43(4):749-758. (PMID: 37558864) Nat Rev Nephrol. 2021 May;17(5):350-363. (PMID: 33627838) Am J Physiol Heart Circ Physiol. 2012 Mar 1;302(5):H1031-49. (PMID: 22058154) Circ Res. 2018 Apr 13;122(8):1094-1101. (PMID: 29475981) Nat Rev Nephrol. 2019 May;15(5):290-300. (PMID: 30804523) Am J Physiol Renal Physiol. 2019 Aug 1;317(2):F361-F374. (PMID: 31215801) Am J Physiol Regul Integr Comp Physiol. 2010 Apr;298(4):R1136-42. (PMID: 20147611) Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F499-508. (PMID: 25007871) Case Rep Nephrol Dial. 2021 Aug 12;11(2):254-260. (PMID: 34595213) Cell Rep. 2020 Feb 4;30(5):1515-1529.e4. (PMID: 32023466) Hypertension. 2004 Nov;44(5):595-601. (PMID: 15452024) Life Sci. 2023 Aug 15;327:121863. (PMID: 37331504) Ann Med. 2012 Jun;44 Suppl 1:S119-26. (PMID: 22713140) Lancet. 2005 Jan 15-21;365(9455):217-23. (PMID: 15652604) Cochrane Database Syst Rev. 2011 Nov 09;(11):CD004934. (PMID: 22071816) Sci Rep. 2019 Jul 30;9(1):11047. (PMID: 31363128) Kidney Int. 2003 Nov;64(5):1772-9. (PMID: 14531810) J Clin Invest. 2015 Nov 2;125(11):4212-22. (PMID: 26524592) Lancet. 2012 Dec 15;380(9859):2224-60. (PMID: 23245609) Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2054-2064. (PMID: 30354256) J Clin Invest. 2015 Nov 2;125(11):4223-38. (PMID: 26485286) Br J Pharmacol. 2019 Jun;176(12):1818-1828. (PMID: 29952002) Hypertension. 2019 Sep;74(3):555-563. (PMID: 31280647) Nutr Rev. 2016 Oct;74(10):645-58. (PMID: 27566757) Clin Sci (Lond). 2020 Dec 23;134(24):3237-3257. (PMID: 33346358) Cell Metab. 2015 Mar 3;21(3):493-501. (PMID: 25738463) Shock. 2021 Nov 1;56(5):782-792. (PMID: 33555842) Am J Physiol. 1978 May;234(5):F357-70. (PMID: 347950) N Engl J Med. 2013 Mar 28;368(13):1229-37. (PMID: 23534562) Nat Med. 2009 May;15(5):545-52. (PMID: 19412173) Clin Sci (Lond). 2022 Jun 17;136(11):879-894. (PMID: 35532133) Lab Invest. 2017 Apr;97(4):432-446. (PMID: 28165470) Am J Hypertens. 2021 Feb 18;34(1):3-14. (PMID: 32725162) J Clin Invest. 2013 Jul;123(7):2803-15. (PMID: 23722907) Pediatr Nephrol. 2008 Mar;23(3):363-71. (PMID: 17990006) Hypertension. 2018 Jul;72(1):19-23. (PMID: 29760151) Nature. 2013 Apr 25;496(7446):518-22. (PMID: 23467095) J Clin Invest. 2015 Nov 2;125(11):4281-94. (PMID: 26485285) Lancet. 2015 Aug 22;386(9995):801-12. (PMID: 25832858) Nature. 2013 Apr 25;496(7446):513-7. (PMID: 23467085) Metabolism. 2012 Apr;61(4):450-8. (PMID: 22075270) J Autoimmun. 2016 Feb;67:90-101. (PMID: 26584738) Lancet. 2016 Jan 30;387(10017):435-43. (PMID: 26559744) |
| معلومات مُعتمدة: | P30 DK079328 United States DK NIDDK NIH HHS; R01 DK120493 United States DK NIDDK NIH HHS; DK120493 Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM); 916912 American Heart Association (AHA) |
| فهرسة مساهمة: | Keywords: hypertension; lymphatics; macrophages; ovaries; renal physiology; testes |
| المشرفين على المادة: | 0 (Sodium Chloride, Dietary) 0 (Antihypertensive Agents) 26NAK24LS8 (Hydralazine) V55S2QJN2X (NG-Nitroarginine Methyl Ester) |
| تواريخ الأحداث: | Date Created: 20240701 Date Completed: 20240716 Latest Revision: 20240718 |
| رمز التحديث: | 20240718 |
| مُعرف محوري في PubMed: | PMC11250109 |
| DOI: | 10.1042/CS20240698 |
| PMID: | 38949825 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1470-8736 |
|---|---|
| DOI: | 10.1042/CS20240698 |